A study in adults to investigate the impact of mild, moderate, and severe hepatic impairment on pharmacokinetics of venglustat compared to participants with normal hepatic function

Trial Identifier: POP16551
Sponsor: Sanofi
Start Date: January 2023
Primary Completion Date: January 2024
Study Completion Date: January 2024
Condition: Liver, Pancreas & Gallbladder - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
GERMANY Kiel, GERMANY, 24105
UNITED STATES, California Rialto, California, UNITED STATES, 92377
UNITED STATES, Florida Miami, Florida, UNITED STATES, 33014
UNITED STATES, Minnesota St. Paul, Minnesota, UNITED STATES, 55114
UNITED STATES, Tennessee Knoxville, Tennessee, UNITED STATES, 37920
UNITED STATES, Texas San Antonio, Texas, UNITED STATES, 78215